Clinical consequences of ADRβ2 polymorphisms

Gregory A. Hawkins, Scott T. Weiss, Eugene R. Bleecker

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations


The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are β-agonists. The gene ADRβ2 encodes the β-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ADRβ2 variations Gly16Arg and Gln27Glu and, more recently, haplotypic variations, have been the focus of numerous pharmacogenetic studies looking at responses to short-acting (SABA) and long-acting β-agonists (LABA) in subjects with asthma. Thus far, a consensus on the effects of ADRβ2 genetic variations has not been reached, although there does appear to be a reproducible adverse effect in subjects homozygous for Arg16 that are regularly treated with SABAs. The complexity of the genotype by response effects observed makes clinical application of ADRβ2 genetic variations limited, and may require the use of detailed haplotypic variation to fully understand the role ADRβ2 plays in regulating β-agonist response.

Original languageEnglish (US)
Pages (from-to)349-358
Number of pages10
Issue number3
StatePublished - Mar 2008
Externally publishedYes


  • Asthma
  • Pharmacogenetics
  • Polymorphisms
  • β-2-adrenergic receptor
  • β-agonist

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Clinical consequences of ADRβ2 polymorphisms'. Together they form a unique fingerprint.

Cite this